Home » Posts tagged with » Switzerland
Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The transaction is expected to help Roche advance the development of its nanopore sequencer through the access to Sequencing by Expansion (SBX), Stratos Genomics’ unique chemistry. Roche said that once developed, […]

Construction begins on Merck Biotech Development Center in Switzerland

Merck has broken ground on the €250 million Merck Biotech Development Center, a new biotech development facility in Switzerland at Corsier-sur-Vevey. The new facility will be used for biotech development and manufacturing for clinical studies. Construction on the biotech development facility is likely to be wrapped up next year with full operations to begin by […]

Continue reading …
ForaCare Suisse launches FOR A 6 GTel diabetes monitoring device

ForaCare Suisse has launched a new cellular multi-functional diabetes monitoring device FORA 6 GTel based on its Lab in the Pocket technology. The Lab in the Pocket technology, which has also been newly launched, is available on the GTel model and FOR A 6 Series products, said the Swiss healthcare technology company. According to ForaCare […]

Continue reading …
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy. Currently, nadofaragene firadenovec is in late-stage development for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). […]

Continue reading …
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

Continue reading …
Galderma launches phase 3 atopic dermatitis trial for nemolizumab

Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment of moderate-to-severe atopic dermatitis. The late-stage clinical trial will feature adult patients, who are randomly grouped in a double-blinded, placebo-controlled study that will assess the efficacy and safety of the […]

Continue reading …
RESTORE clinical trial of STR001 : Strekin completes patient enrollment

RESTORE clinical trial of STR001 : Swiss biopharma company Strekin has wrapped up patient enrollment in a phase 3 study, called RESTORE, for evaluating its small molecule STR001 in patients after a sudden sensorineural hearing loss (SSNHL) event. The late-stage trial is a global, randomized, placebo-controlled study, which will feature 165 patients at nearly 25 […]

Continue reading …
Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis. As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will […]

Continue reading …
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics

Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]

Continue reading …
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon

Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]

Continue reading …
Page 1 of 212